Characterization of American teduglutide consumers from 2015 to 2020: A large database study. Issue 3 (31st August 2021)

• Record Type: Journal Article
• Authors: Loutfy, Adam; Kurin, Michael; Shah, Raj; Davitkov, Perica
• Is Part Of: JPEN, Journal of parenteral and enteral nutrition. Volume 46:Issue 3(2022)
• Page Start: 646
• Page End: 651
• Publication Date: 2021-08-31
• Subjects: epidemiology -- heart failure -- malignancy -- nutrition -- parenteral nutrition -- pharmacology -- short bowel syndrome -- teduglutide; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; 615.85484
• DOI: 10.1002/jpen.2221
• Languages: English
• ISSNs: 0148-6071

Abstract

Abstract: Introduction: Teduglutide, a glucagon‐like peptide‐2 analog, is a novel therapy for intestinal failure that reduces need for parenteral support, especially in patients without a functional terminal ileum or colon. It can also predispose patients to accelerated progression of gastrointestinal (GI) malignancy and fluid overload. We demographically and clinically characterized American patients prescribed teduglutide. Methods: The Explorys database is an aggregate of deidentified patient data from dozens of US healthcare systems. We used SNOMED classification to identify patients prescribed teduglutide from 2015 to 2019. Through the browse cohort feature we determined the demographics, postsurgical anatomy, comorbidities, and indication for teduglutide use among these patients. Results: Of approximately 72 million patients, 170 were prescribed teduglutide. A large majority were female (70.6%). Most common etiologies of short‐bowel syndrome were intestinal obstruction (52.9%) and Crohn's disease (41.2%). Common postsurgical anatomy included total colectomy (41.2%) and ileostomy. Common incident symptoms included abdominal pain (41.2%) and nausea (23.5%). Thirty (17.6%) patients were prescribed teduglutide despite comorbid heart failure, and 5.9% despite prior GI malignancy. A total of 11.8% of patients had a history of benign GI neoplasms before starting teduglutide. A total of 5.9% of patients had posttreatment formation of colon polyps. Conclusion: In a large American database, the teduglutide prescription is rare. Only a minority have postsurgical anatomy associated with the most robust response to teduglutide. Serious adverse events appear rare, but a substantial number of patients are at risk for adverse effects because of the presence of comorbid heart failure or GI neoplasm.